Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enzyme replacement in Tay-Sachs disease.

B U von Specht, B Geiger, R Arnon

    Neurology
    |June 1, 1979
    PubMed
    Summary

    Enzyme replacement therapy using intrathecal hexosaminidase A injections did not improve outcomes for Tay-Sachs disease patients. Despite reducing GM2 in serum, the treatment failed to dissolve brain lesions or show clinical benefits.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Development and application of a low-noise, high-speed optical detector module for carbon density fluctuation measurements on Wendelstein 7-X.

    The Review of scientific instruments·2026
    Same author

    Measurement of Stark-split beam and carbon charge exchange emissions for simultaneous B-field and temperature/rotation analysis at DIII-D.

    The Review of scientific instruments·2024
    Same author

    Enhancing Thomson scattering polychromator performance with multi-pass spectral filters.

    The Review of scientific instruments·2024
    Same author

    Visible core spectroscopy at Wendelstein 7-X.

    The Review of scientific instruments·2024
    Same author

    Design study of an edge current density diagnostic using new high-performance single-channel beam emission spectrometers at DIII-D.

    The Review of scientific instruments·2022
    Same author

    Pedestal fluctuation measurements with charge exchange imaging at the DIII-D tokamak.

    The Review of scientific instruments·2022

    Area of Science:

    • Biochemistry
    • Neurology
    • Genetics

    Background:

    • Tay-Sachs disease is a rare genetic disorder caused by a deficiency of the enzyme hexosaminidase A.
    • This deficiency leads to the accumulation of GM2 gangliosides in nerve cells, causing progressive neurodegeneration.
    • Current treatment options for Tay-Sachs disease are limited.

    Observation:

    • Two individuals with Tay-Sachs disease, a 14-month-old child and a 7-week-old infant, received enzyme replacement therapy.
    • Treatment involved weekly intrathecal injections of pure hexosaminidase A.
    • Serum GM2 levels decreased significantly post-injection, but electron microscopy revealed no dissolution of brain GM2 cytoplasmic bodies.

    Findings:

    • Intrathecal hexosaminidase A administration effectively cleared GM2 from the serum.

    Related Experiment Videos

  • The treatment did not resolve the characteristic GM2 membranous cytoplasmic bodies in the brain.
  • No significant clinical improvement was observed in either patient despite prolonged treatment.

    • Implications:

    • Enzyme replacement therapy via intrathecal injection of hexosaminidase A is not a beneficial treatment for Tay-Sachs disease.
    • The route of administration and the inability to clear brain-based GM2 deposits are significant limitations.
    • Further research into alternative therapeutic strategies is warranted for Tay-Sachs disease.